ASCO GU: Evaluation of Sexual Function on a Randomized Trial of a Prostate Rectal Spacer

Orlando, Florida USA (UroToday.com) A phase III trial was performed using an absorbable hydrogel (SpaceOAR System) to provide space between the prostate and rectum for men undergoing dose-escalated (to 79.2 Gy IMRT) prostate radiation therapy.

ASCO GU 2017: Assessment of urologists experience with abiraterone acetate and with a real-world trial: Results obtained from a Canadian Observational Study in Metastatic Cancer of the Prostate (COSMiC). - Session Highlights

Orlando, Florida USA (UroToday.com) At this years genitourinary cancers symposium in Florida, Dr. Feifer presented data which states that incorporating Abiraterone into clinical practice of Urologists is a realistic and feasible process. The Canadian Observational Study in Metastatic Cancer of the Prostate (COSMiC) is a non-Interventional observational study phase IV clinical trial (NCT02364531).

ASCO GU 2017: Informed decision making (IDM) for prostate cancer (PCa) screening in a high-risk population. - Session Highlights

Orlando, Florida USA (UroToday.com) Puneet Dhillon from Southfield Michigan addressed the important issue of informed decision making to a high risk population in his abstract presented at the 2017 Genitourinary Cancer Symposium. His team recognised the potential that health-education may reduce disparities.

ASCO GU 2017: Best of Journals: Prostate Cancer - Medical Oncologist Perspective - Session Highlights

Orlando, Florida USA (UroToday.com) Joshua Lang, University of Wisconsin, presented review of new molecular information in prostate cancer. Metastatic castrate-resistant prostate cancer (mCRPC) now has a multitude of regimens and sequence of administration to consider.

ASCO GU 2017: Best of Journals: Prostate Cancer - Radiation Oncologist Perspective - Session Highlights

Orlando, Florida USA (UroToday.com) Robert Den, Sidney Kimmel Medical College of Thomas Jefferson University, presented review of literature from a radiation oncologist perspective. The CHHIP trial assessed hypofractionation versus conventional IMRT with 3 arms 74Gy (standard) vs 60Gy or 57Gy (hypofractionated) regimens, respectively.

ASCO GU 2017: Best of Journals: Prostate Cancer - Surgeon's Perspective - Session Highlights

Orlando, Florida USA (UroToday.com) Jim C Hu, Cornell University, presented review best journal articles in prostate cancer. The PLCO study was re-examined with prior analyses highlighting contamination of 52% being a chief limiting factor deriving meaningful conclusions regarding survival outcomes.

ASCO GU 2017: Year in Review - Session Highlights

Orlando, Florida USA (UroToday.com) Dr. James Catto, Editor in Chief of European Urology presents a review of the most important publications in the field of prostate cancer in 2016. The field of prostate cancer has seen a significant number of advances in the last years ranging from advances in imaging, biopsy technique, the radical treatment of oligometastatic disease and the use of docetaxel in the management of hormone sensitive metastatic prostate cancer along others.

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe